BMS-986299

BMS‑986299 is a first-in-class, small molecule agonist of the NOD-, LRR-, and pyrin-domain containing protein 3 (NLRP3) inflammasome, developed by Bristol Myers Squibb for cancer immunotherapy. It binds to and activates NLRP3, promoting inflammasome-mediated secretion of pro-inflammatory cytokines such as interleukin‑1β (IL‑1β), IL‑8, IL‑18, G-CSF, and IL‑6. This activation enhances adaptive immune responses and T-cell memory formation. In preclinical models and early-phase clinical trials in advanced solid tumors, intratumoral administration of BMS‑986299 increased tumor-infiltrating lymphocytes (CD8+ CTLs, CD4+ T cells), natural killer cells, tumor-associated macrophages (TAMs), and induced a proinflammatory tumor microenvironment that may synergize with immune checkpoint inhibitors like nivolumab or ipilimumab. The drug is being investigated primarily for advanced solid tumors[1][2][3][5].

Other names

BMS986299BMS-986299BMS 986299compound 112 [WO2018152396A1]VS58MO4P47VS-58MO4P47VS 58MO4P472242952-69-6